Corindus Vascular Robotics (OTC:CVRS) said today that its CorPath GRX 2nd-generation vascular robot-assisted surgery platform was used in its 1st commercial procedures.

The robotic platform was used early this month at the NewYork-Presbyterian hospital, UC San Diego Health and University of Virginia Health System in robotic-assisted PCI procedures, the company said. It began early installations of the systems in January, with a full commercial launch slated for later this month.

“Completion of these initial CrPath GRX procedures marks an important step forward in vascular robotics. We are committed to continuing to develop and deliver innovative products to advance the field of cardiovascular robotics and support better patient outcomes,” prez & CEO Mark Toland said in a press release.

Corindus said that hospital programs that used the robotic system provided positive feedback on their initial forays with the devices.

“We are proud to be among the group of premier hospitals that performed the first cases in the world using the new CorPath GRX System. The enhancements provided by CorPath GRX represent a dramatic improvement in the capabilities in robotic PCI and have the potential to provide significant improvements in patient care,” Dr. Manish Parikh of NewYork-Presbyterian said in prepared remarks.

“I am impressed with the additional capabilities of the new GRX System. The redesigned bedside unit, intuitive control console, and especially guide catheter control further facilitate complex PCI procedures. It also enables me to train other interventionalists and fellows in state-of-the-art robotics,” Dr. Ehtisham Mahmud of the Sulpizio Cardiovascular Center said in a prepared statement.

Waltham, Mass.-based Corindus won FDA 510(k) clearance for the next-gen robotic system last October, adding several features to system including the ability to control the guide catheter in 1mm increments to precisely position balloon or stent catheters during percutaneous coronary interventions.